Abbott Wins FDA Nod for World’s First Dual Glucose-Ketone Sensor, Bolstering Diabetic Ketoacidosis Prevention

August 30, 2026

MDO Online USA

Overview

Abbott’s Libre Duo 10 Day has received FDA authorization as the world’s first Continuous Glucose Monitoring (CGM) system capable of continuously tracking both glucose and ketone levels. Developed to prevent diabetic ketoacidosis (DKA), this system also meets the FDA’s new integrated continuous glucose and ketone monitoring (iCGK) standard. This approval represents a significant advance in DKA early detection and management.

In Depth

Key Findings

MDO Online reported on August 26, 2026, that Abbott’s innovative Libre Duo 10 Day system has secured authorization from the U.S. Food and Drug Administration (FDA). This device stands as the world’s first Continuous Glucose Monitoring (CGM) system capable of continuously monitoring both glucose and ketone levels, specifically designed for the prevention and early intervention of diabetic ketoacidosis (DKA). The approval represents a groundbreaking achievement as the first product to comply with the FDA’s newly established Integrated Continuous Glucose and Ketone Monitoring (iCGK) standard.

Technical and Clinical Details

The Libre Duo 10 Day is a small, discreet sensor worn on the patient’s upper arm, providing real-time measurements of both glucose and ketone levels for up to 10 days. This integrated sensor builds upon the established CGM technology of the existing FreeStyle Libre series while incorporating high-precision ketone measurement capabilities. The system features data-driven alerts that notify users before their ketone levels reach a dangerous threshold, prompting rapid action prior to DKA onset. Clinical data confirm Libre Duo 10 Day’s high reliability in detecting rising ketone levels, which are critical early indicators of DKA. This provides extremely valuable information for daily management, especially for Type 1 diabetes patients and those at high risk of DKA during sick days.

Background and Industry Context

In diabetes management, while blood glucose control is essential, insulin-dependent patients face the risk of DKA, a severe condition caused by ketone accumulation due to insulin deficiency or specific circumstances. Traditional CGMs focused solely on glucose levels, necessitating separate manual measurements for ketones. This posed a significant challenge for early DKA detection and prevention. Abbott’s Libre Duo 10 Day addresses this unmet need, promising to transform the standard of diabetes care. The evolution of wearable medical technology is progressing towards empowering patient self-management and improving the efficiency of healthcare provider interventions, with this device at the forefront.

Strategic Significance and Outlook

MDO Online analyzes that this FDA authorization will further solidify Abbott’s leadership in the diabetes medical device market. With the introduction of Libre Duo 10 Day, patients are expected to benefit from safer and more comprehensive diabetes management, potentially reducing the burden of DKA-related emergency care. Furthermore, this dual-sensing technology holds the potential for broader applications in monitoring other biomarkers and diseases in the future, contributing to the evolution of personalized healthcare. Investors are closely watching the long-term market impact of this technology and its socioeconomic value through healthcare cost reduction.

Source: https://www.mddionline.com/diabetes/abbott-wins-fda-nod-for-world-s-first-dual-glucose-ketone-sensor

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.